HRTX — Heron Therapeutics Cashflow Statement
0.000.00%
- $251.21m
- $385.78m
- $144.29m
- 42
- 70
- 11
- 36
Annual cashflow statement for Heron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -227 | -221 | -182 | -111 | -13.6 |
| Depreciation | |||||
| Non-Cash Items | 52.6 | 49.4 | 42.7 | 32.1 | 16.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13 | -35.1 | -10.5 | 16.8 | -27.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -185 | -203 | -147 | -58.8 | -22.5 |
| Capital Expenditures | -6.81 | -3.02 | -1.82 | -1.54 | -1.71 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 216 | 35.8 | -1.5 | 19.5 | 20.4 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 209 | 32.7 | -3.32 | 18 | 18.7 |
| Financing Cash Flow Items | 0.026 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.11 | 156 | 75.1 | 54.1 | 0.94 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 33.2 | -14.6 | -75.2 | 13.3 | -2.88 |